MedPath

Comparative Efficacy of Treatment Regimens for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

A network meta-analysis compared the efficacy of various treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma, highlighting daratumumab-containing therapies and VRd as the most effective in improving progression-free survival and overall survival.

Introduction

Multiple myeloma (MM) treatment has evolved, especially for patients ineligible for stem cell transplantation due to age or comorbidities. This study aimed to compare the efficacy of different therapies for these patients through a network meta-analysis (NMA).

Methods

The NMA included data from large randomized controlled trials (RCTs) such as SWOG S0777, ENDURANCE, MAIA, and ALCYONE. It focused on progression-free survival (PFS) and overall survival (OS), using lenalidomide/dexamethasone (Rd) as the reference comparator.

Results

Daratumumab-containing treatments (D-Rd, D-VMP) and bortezomib/lenalidomide/dexamethasone (VRd) showed the highest probabilities of being more effective than Rd for both PFS and OS. D-Rd was ranked as the most effective treatment.

Conclusions

The findings suggest that D-Rd, D-VMP, and VRd are the most effective treatments for improving PFS and OS in transplant-ineligible patients with newly diagnosed multiple myeloma. This analysis may guide treatment selection for this patient population.

Supplementary Information

The online version contains supplementary material available at 10.1007/s12325-022-02083-8.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Key Trials in Transplant-Ineligible NDMM

Exploring the latest advancements and considerations in the treatment of transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients, focusing on key trials and personalized treatment strategies.

FDA Approvals Expand Initial Treatment Options for Multiple Myeloma

The FDA has approved new treatment options for newly diagnosed multiple myeloma patients, including daratumumab for transplant-eligible patients and isatuximab for those not eligible for a transplant. These approvals are based on clinical trials showing improved outcomes with four-drug regimens.

Tandem vs. Single Autologous Stem Cell Transplant in Multiple Myeloma: A Comprehensive Analysis

A recent study in *Nature* investigates the efficacy of single versus tandem autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma.
The analysis suggests that tandem ASCT may offer a survival advantage in specific high-risk patient subgroups.

Daratumumab Plus VRd Improves Outcomes in Transplant-Ineligible Multiple Myeloma Patients

The phase 3 CEPHEUS trial demonstrated that adding daratumumab to VRd significantly improved outcomes for transplant-ineligible newly diagnosed multiple myeloma patients.
The quadruplet regimen achieved a 60.9% minimal residual disease (MRD) negativity rate compared to 39.4% with VRd alone, demonstrating a significant increase in treatment depth.

CEPHEUS Trial Supports Quadruplet Therapy with Daratumumab as New Standard in Multiple Myeloma

The CEPHEUS trial suggests that transplant-ineligible multiple myeloma patients may benefit from quadruplet regimens in the frontline setting, leading to deeper responses and improved progression-free survival.
The study builds on the MAIA trial, indicating that daratumumab-based quadruplet therapy could surpass previous benchmarks for treating transplant-ineligible patients.

Belantamab Mafodotin Plus VRd Shows Promising Efficacy in Newly Diagnosed Multiple Myeloma

The GEM-BELA-VRD trial showed a 94% objective response rate with belantamab mafodotin plus VRd in transplant-eligible, newly diagnosed multiple myeloma patients.
Complete response rates improved over time, reaching 82% after one year of maintenance therapy, with minimal residual disease negativity in 91.2% of patients.

Belantamab Mafodotin, Pomalidomide, and Dexamethasone Show Promise in Triple-Class Exposed Multiple Myeloma

A phase 1/2 trial evaluated belantamab mafodotin, pomalidomide, and dexamethasone (B-Pd) in patients with triple-class exposed relapsed/refractory multiple myeloma.
The combination therapy demonstrated an overall response rate of 59% in heavily pretreated patients, indicating notable efficacy.

Daratumumab-Based Regimens Deepen Responses and Improve MRD Negativity in Multiple Myeloma

Daratumumab plus lenalidomide maintenance significantly increased MRD-negative conversion rates compared to lenalidomide alone in transplant-eligible newly diagnosed multiple myeloma patients.
The addition of daratumumab to VRd improved MRD negativity rates in transplant-ineligible or deferred newly diagnosed multiple myeloma patients.

FDA Approves Darzalex Faspro Quadruplet Regimen for Transplant-Eligible Multiple Myeloma

The FDA has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant.
The approval was based on the Phase 3 PERSEUS study, which demonstrated a 60% reduction in the risk of disease progression or death with the D-VRd regimen compared to VRd alone.

MRD Negativity as a Surrogate Endpoint for PFS in Multiple Myeloma

Achieving minimal residual disease (MRD) negativity is increasingly recognized as a crucial endpoint in multiple myeloma treatment, indicating deeper remission and improved outcomes.
Meta-analysis of six randomized clinical trials suggests that MRD status could serve as a surrogate endpoint for progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM).

Reference News

[1]
Treatment Regimens for Transplant-Ineligible Patients With ...
pmc.ncbi.nlm.nih.gov · Mar 5, 2022

A network meta-analysis compared treatments for transplant-ineligible newly diagnosed multiple myeloma patients, finding...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy